quanta receives fda  clearance forthe sc hemodialysis systemsetting the stage for us market launchalcester warwickshire uk  january  quanta dialysis technologies ltd “quanta” or “the company” a british medical technology pioneer developing innovative dialysis products and services for the global market today announces it has received  clearance from the us food and drug administration “fda” to market its small and simple high performance hemodialysis system sc this critical milestone enables quanta to bring to the american market its portable device that can provide a dialysis dose equivalent to todays standard of care but in a compact easytouse format suitable for a range of care settings“kidney failure is one of the costliest health conditions for the american health system the imperative for better value in healthcare coupled with new challenges driven by  has amplified the need to reimagine how hemodialysis is delivered across a variety of settings” said john e milad ceo quanta “this will be a pivotal year for quanta as we build our us presence and bring our next generation hemodialysis system to a community ripe with need”the sc system in the usthere are more than half a million patients requiring hemodialysis in the united states the vast majority of these patients receive dialysis threetimesaweek with a minority receiving more frequent therapy unlike other portable hemodialysis systems sc can deliver the higher dialysate flow rates typically used to provide conventional threetimesaweek prescriptions while also offering the flexibility for more frequent longer and gentler treatments tailored to patients’ needs the small lightweight design of sc makes the device portable allowing for dialysis treatments to be brought to patients and the simple intuitive user interface makes dialysis accessible to a broad range of healthcare professionalsstory continuesin preparation for commercial launch quanta continues to develop its us team and operations following the appointment earlier this year of the company’s president of north america john lipman quanta has also recently hired a head of chronic sales and a head of clinical support while also building a dedicated usbased team that includes training customer care and technical staff to support the company’s customers and usersto complement sc quanta will introduce a suite of related products and services this includes an optional portable water purification module that will enable sc to be easily moved around and to be operated in a wide range of settings both with and without a centralized water system and a secure cloudbased digital health offering that will simplify and automate treatment data capture and reporting negating the need to create and store manual recordsbrigitte schiller md chief medical officer of satellite healthcare in san jose ca and member of quanta’s medical advisory board said “sc is a welcome new technology that addresses the need for simpler more portable dialysis systems that can deliver treatment flexibility innovations such as this can facilitate more individualized care and improved patient experience playing an important role in the transformation of the current care model”andrew lazar md chief of nephrology at ahuja medical center in cleveland oh said “i’m excited about the cartridgebased technology and high dialysate flow rates of sc the versatility portability and simplicity of this device combined with a modular approach to water purification offer something for many different care environments i can use sc in skilled nursing facilities sled or on regular floors in the hospital dialyzing five days a week isn’t always an option and sc provides muchneeded clinical flexibility”following extensive clinical piloting with the national health service nhs in england sc became commercially available in the uk last year playing a vital role in supporting the increased need for more simple flexible dialysis devices in the hospital and the home particularly during the rise of the  pandemic as reported in a recently published study komenda et al kidney medicine  sc combines the power and performance of larger conventional dialysis machines with the convenience of a compact portable user friendly device making sc a muchneeded addition to existing dialysis treatment optionsendsfor more information about quanta please contactquantajohn e miladchief executive officert   e enquiriesquantadtcom consilium strategic communicationsamber fennell  matthew neal  lindsey neville t    e quantaconsiliumcommscomabout hemodialysishemodialysis is a life sustaining treatment for patients with kidney failure to help normalize blood chemistry and remove waste products and excess fluidsabout quanta and scheadquartered in the uk quanta is an international commercialstage technologyenabled dialysis innovator that aims to improve dialysis experiences and to help people live more freely through products and services that are easytouse versatile and empoweringquanta’s lead product sc is a small and simple high performance hemodialysis system designed to provide greater freedom and flexibility in the delivery of life sustaining dialysis treatments sc is commercially available in the uk where it has been successfully used to treat patients across a range of care settings from the icu and the clinic to the homethe innovative and patented technology behind sc is based on a design breakthrough that allows all dialysate fluid management to be conducted on a small lightweight disposable cartridge the simpletouse and digitally connected design of sc is intended to empower more patients to take control of their lives with selfcare and home dialysis meanwhile as a compact portable and versatile device sc provides flexibility to deliver dialysis across a wide range of use environments and prescriptionsfor more information please visit our website quantadtcom